The Trump administration's Department of Justice requested a federal court pause Louisiana's legal challenge against eased FDA restrictions on the abortion pill mifepristone. Louisiana's lawsuit, filed by the Attorney General and an individual plaintiff, challenges the FDA policy allowing mifepristone to be distributed by mail. The DOJ argues that pausing the challenge is appropriate because the FDA is currently conducting a safety review of mifepristone, which could take about a year. The DOJ filing suggests that granting the plaintiff's request to end mail-order distribution now might be unnecessary if the FDA review leads to restoring in-person dispensing requirements. Susan B. Anthony Pro-Life America, a pro-life group, has been advocating for the rollback of the Biden administration's mifepristone regulations.
about 1 month ago
Louisiana Attorney General Liz Murrill and plaintiff Rosalie Markezich sued the FDA in October 2025.1 2
The suit challenges the Biden-era policy allowing mail-order mifepristone, citing Markezich's coercion by her boyfriend using pills from a California doctor.1 2
Louisiana bans most abortions from conception, but out-of-state mail deliveries undermine the law.2
On January 27, 2026, the DOJ filed to pause the lawsuit.1 2
It argues an FDA safety review of mifepristone is underway and could take a year, making immediate court action disruptive.1 2
The filing notes prior FDA risk assessments lacked adequate consideration.2
Marjorie Dannenfelser of Susan B. Anthony Pro-Life America called the DOJ action "unacceptable," slamming doors on harmed women and babies.1 2
She accused the FDA of slow-walking a promised study by HHS Secretary Robert F. Kennedy Jr., delaying action past 2027 midterms.1 2
Jennie Bradley Lichter of March for Life urged swift restoration of in-person requirements, citing a Marist Poll where 59% favor doctor visits.1
Murrill denounced the filing as an "affront to our sovereignty and the dignity of women and the unborn."1 2
She highlighted 1,000 dangerous abortions monthly in Louisiana and called for FDA support against "abortion extremists" like governors Newsom and Hochul.1 2
Alliance Defending Freedom's Kristen Waggoner echoed demands for the administration to back Louisiana.1
ACLU's Julia Kaye accused the Trump administration of defending its own authority over mifepristone, not access.1
She deemed both state challenges and FDA reviews wrong on law, science, and public opinion.1
Father Tadeusz Pacholczyk stressed doctors' duty for in-person oversight, criticizing mail-order as a lower standard.2
The FDA approved a generic mifepristone in September 2025 despite pro-life objections.1 2
This week, HHS rescinded guidelines potentially forcing pharmacies to dispense abortion pills.2
The filing follows VP Vance's March for Life speech assuring pro-life allies, amid priorities like Hyde Amendment protection.1
Pro-life groups warn delays harm women and children, with chemical abortions killing more than fentanyl, cocaine, or heroin combined.1
USCCB advocates restoring prior safety protocols, emphasizing risks to mothers and preborn.1
Over 60% of U.S. abortions use mifepristone-misoprostol, fueling state-federal tensions post-Dobbs.1
Assess Catholic doctrine on abortion amid U.S. mifepristone litigation
Catholic doctrine unequivocally affirms the sanctity of human life from the moment of conception, rendering direct abortion—whether surgical or chemical—gravely immoral and always to be opposed. In the context of ongoing U.S. litigation surrounding mifepristone, a drug used in chemical abortions, the Church maintains that such practices pose profound threats to both unborn life and women's health, urging robust legal and regulatory safeguards. The United States Conference of Catholic Bishops (USCCB) has consistently advocated for restrictions on mifepristone, highlighting ethical violations, exaggerated safety claims, and high rates of serious complications, while calling for policies that prioritize true maternal support over abortion facilitation.
At the heart of Catholic moral teaching is the absolute respect due to every human person from conception, as "human life must be respected and protected absolutely from the moment of conception." This principle, enshrined in the Catechism of the Catholic Church, underscores that the unborn child is a distinct human being whose right to life is inviolable, forming the bedrock for rejecting any deliberate termination of pregnancy.
The USCCB's Forming Consciences for Faithful Citizenship elaborates that "abortion, the deliberate killing of a human being before birth, is never morally acceptable and must always be opposed." It identifies abortion and euthanasia as "preeminent threats to human life and dignity because they directly attack life itself, the most fundamental good and the condition for all others." Laws legitimizing abortion are deemed "profoundly unjust and immoral," prompting the Church to support "constitutional protection for the unborn and legislative efforts to end abortion." This stance reflects enduring principles, as articulated in historical USCCB testimony post-Roe v. Wade, where Cardinal John Krol emphasized abortion's scale—"one abortion every 20 seconds"—as a national tragedy demanding constitutional correction to defend "the most fundamental of all rights, the right to life itself."
Mifepristone, used in telemedicine chemical abortions, falls squarely under this doctrinal condemnation as a direct attack on innocent life. The USCCB, alongside Catholic healthcare organizations, has pressed the FDA to address mifepristone's dangers, noting that "the totality of the medical evidence shows that the FDA has an ethical obligation to protect women from the dangers that mifepristone presents to women's health and safety." A comprehensive study cited in their 2025 joint letter revealed that 10.93% of over 865,000 chemical abortion cases from 2017-2023 involved serious adverse events like infection, sepsis, hemorrhage, and incomplete abortion—rates "22 times higher than previously acknowledged by the FDA."
Key ethical concerns include "inadequate informed consent due to misleading adverse event data, insufficient disclosure of alternatives, increased risks of coercion especially for vulnerable populations, promotion of patient and provider dishonesty," and the FDA's removal of safeguards like in-person visits and ultrasounds. These violate principles of autonomy, beneficence, and non-maleficence, prioritizing "abortion ideology over public transparency." Recent USCCB correspondence reinforces this, urging Congress to "prevent and prohibit policies that facilitate and promote access to chemical abortion through the Food and Drug Administration (FDA)," as "mothers in need and their families deserve authentic support."
In the broader landscape of U.S. mifepristone litigation—challenging FDA approvals and expansions—the Church's voice remains resolute, opposing measures that enshrine abortion access. Letters against the Women's Health Protection Act (WHPA) decry it as an "extreme bill [that] would impose abortion on demand nationwide at any stage of pregnancy," eliminating protections like parental notification, informed consent, and facility safety standards while forcing taxpayer funding and conscience violations.
Drawing on papal authority, these documents quote St. John Paul II: "The greatness of the United States lies especially [in its] respect for the dignity and sanctity of human life in all conditions and at all stages of development." Pope Francis warns that the "killing [of unborn children] in huge numbers, with the endorsement of States, is a serious problem that undermines the foundations of the construction of justice." Abortion is "the opposite of women's health care," never medically necessary to save a mother's life—delivery suffices—and it harms women, particularly the poor.
The USCCB promotes a "culture of life" through alternatives: supporting childbirth, adoption, poverty alleviation, healthcare, and palliative care, urging collaboration across sectors. Politics, as a "noble mission to promote the common good," demands weighing such "inescapable moral challenges."
Catholic doctrine provides an unchanging framework: abortion, including via mifepristone, is intrinsically evil, demanding opposition in law and policy. Amid U.S. litigation, the USCCB substantiates this with evidence of health risks and ethical lapses, advocating protections for life and authentic support for women. This consistent witness—from the Catechism to recent letters—calls Catholics to faithful citizenship, prioritizing the vulnerable unborn while fostering a just society.